Skip to main content

Published locations for Enasidenib vs. standard of care therapies prolongs survival in patients with R/R AML with IDH2 mutation

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Enasidenib vs. standard of care therapies prolongs survival in patients with R/R AML with IDH2 mutation

User login

  • Reset your password
  • /content/enasidenib-vs-standard-care-therapies-prolongs-survival-patients-r/r-aml-idh2-mutation
  • /hematology-oncology/article/246631/aml/enasidenib-vs-standard-care-therapies-prolongs-survival